Antroquinonol, Committed to Innovative & Breakthrough Therapy to Improve Quality of Life
Exhibitor: GOLDEN BIOTECHNOLOGY CORP.
Date: 2022-07-30
Booth No.: R309
Antroquinonol ( HOCENA ), Committed to Developing Innovative & Breakthrough Therapy to Improve Quality of Life
Welcome visist us at R309, Pharma Area, 4F. during 2022 Bio Asia Taiwan.( 7/28-31, Taipei Nangang Exh. Center Hall 2)
Antroquinonol (HOCENA) is a new small molecule drug (NCE) and distinguished from other developing drugs for COVID-19 by its convenient oral administration design and multi-functional effects on anti-viral, anti-inflammation and anti-fibrosis characteristics revealed by studies.
Golden Biotechnology Corporation (GBC, GoldenBiotech) (TPEx: 4132), founded in 2002, is a leading Taiwanese biopharmaceutical company. GoldenBiotech focuses on discovery and clinical development of innovative therapeutic new drugs (NCE), and dedicated to improving quality of life by developing products that prevent and treat diseases.
Antroquinonol was discovered from GoldenBiotech's own screening platforms. Antroquinonol® (trade name HOCENA® ) has been granted more than 140 patents worldwide for its structure, preparation and applications in oncology, cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases and infectious diseases. Since 2013, Antroquinonol® was authorized Phase II clinical trial on NSCLC by US FDA and Taiwan FDA and trial completed in 2019. The clinical trials on acute myeloid leukemia (AML) has also completed in 2020, and the multi-national trials on pancreatic cancer expected to accomplish in 2022. Orphan Drug Designations (ODD) were obtained in treatment of pancreatic cancer (US #14-4608 & EU), AML (US#15-4763) and hepatocellular carcinoma (US#15-4881).
GoldenBiotech has completed the Phase 2 multi-national COVID-19 clinical trial in the US, Peru and Argentina and the trial has been unblinded clinical results in Jan. 2022.
Antroquinonol® is an oral new drug which exhibits a broad spectrum of activities against malignancies in-vivo and in-vitro, and offers a better solution than the single-action compounds the industry developed so far. Antroquinonol’s multiple, simultaneous, and synergistic actions enable positive outcomes. Antroquinonol® can be used as a monotherapy, combination- or adjuvant-therapy to complement other drugs, or as a best supportive care.
Therefore, Golden Biotechnology is committed to the research and development of ideal drugs that can demonstrate innovative, breakthrough therapy to improve the Quality of Life.
More Exhibitor's Press Release
- Home Visual Acuity tester- Don't let pseudomyopia become real myopia EYEMIKAN BIOTECH INC. / 2022-09-21
- Third-party Study Report: Investigation of Shear Stress Exerted on Proteins by Different Pump System LEVITRONIX GMBH TAIWAN BRANCH / 2022-08-01
- Third-party Study Report: Investigation of Shear Stress Exerted on CHO Cell by Different Pump System LEVITRONIX GMBH TAIWAN BRANCH / 2022-08-01
- Third-party Study Report: Pump Particle Shedding Evaluation LEVITRONIX GMBH TAIWAN BRANCH / 2022-08-01
- Bio Asia-Taiwan 2022 Opening! Vitae Biomedical showcases the new outstanding achievements. VITAE BIOMEDICAL CO. LTD. / 2022-07-30
- Joint Genomic Analytics Platform from Advantech, GARAOTUS and WASAI GARAOTUS (SYSTEX GROUP) / 2022-07-30
- FDA Grants the Pre-EUA Meeting Request by GoldenBiotech’s Applied Antroquinonol to Treat COVID GOLDEN BIOTECHNOLOGY CORP. / 2022-07-30
- Italy participates for the third time in BIO ASIA with 7 companies ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2022-07-29
- AcadeMab makes its mark at 2022 BIO USA ACADEMAB BIOMEDICAL INC. / 2022-07-28
- Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutraliz ACADEMAB BIOMEDICAL INC. / 2022-07-28
- CAMCEVI 42 mg Injection Emulsion Launched in the U.S. for the Treatment of Advanced Prostate Cancer FORESEE PHARMACEUTICALS CO., LTD. / 2022-07-27
- Foresee Announces European MAA Approval of CAMCEVI for the the Treatment of Advanced Prostate Cancer FORESEE PHARMACEUTICALS CO., LTD. / 2022-07-27
- TaiMed is your reliable biologics CDMO partner TAIMED BIOLOGICS INC. / 2022-07-27
- US FDA NDIN approval for Deglusterol, a new dietary ingredient for blood sugar control CAREGEN CO., LTD. / 2022-07-27
- 2022BioAsiaTaiwan-Golden Biotech Seminar Registration_Innovative Breakthrough_COVID-19 to Oncology GOLDEN BIOTECHNOLOGY CORP. / 2022-07-27
- Amaran Biotech Introduces the First Fully-Automated Robotic Aseptic Filling Line in Taiwan AMARAN BIOTECHNOLOGY, INC. / 2022-07-25
- "Montefarmaco’s portfolio covers the main segments of the self-medication market" MONTEFARMACO OTC SPA / 2022-07-22
- TMU BioMed Accelerator | 2022 Batch Demo Day (Register Now) TAIPEI MEDICAL UNIVERSITY / 2022-07-22
- BUCHI wins Swiss Export Award 2022 BUCHI TAIWAN CO., LTD. / 2022-07-21
- Automation and innovative design of BUCHI’s new Spray Dryer markedly improve spray drying performanc BUCHI TAIWAN CO., LTD. / 2022-07-21
